Quantitation of the Early Effects of Radiation and Hormonal Therapy on Hemoglobin Levels in Men Treated for Prostate Cancer

Ryan Smith, MD
University of Pennsylvania Cancer Center
Ultima Vez Modificado: 4 de noviembre del 2001

Share article


Presenter: J. Wilson

Affiliation: University of Pennsylvania

Background
Anemia has been shown to be a prognostic factor in head and neck and cervical cancer. However, unless hemoglobin falls to values <8 mg/dl, it is rarely treated, even though it is associated with hypoxia and poorer outcome. There are limited studies evaluating radiation's effect on erythropoiesis in prostate cancer. Radiation effects the bone marrow directly and hormones may block androgen's stimulation of erythropoiesis. Therefore, the effect of radiation and hormones may be additive.

Materials and Methods

  • This is a retrospective study of 198 men with stage T1-4N0M0 prostate cancer.
  • Hemoglobin levels were measured before and after treatment and compared to determine the effect of radiation and hormonal ablation on the development of anemia
  • 54 patients were treated with prostate irradiation alone (less than a 12x12 cm field or brachytherapy)
  • 46 patients were treated with prostate irradiation with 4-6 months of androgen ablation
  • 55 patients were treated with whole pelvis irradiation alone
  • 43 patients were treated with whole pelvis irradiation with 4-6 months of androgen ablation.
  • Hormonal ablation consisted of leuprolide +/- anti-androgen therapy
  • There was a trend toward more T1-T2 patients that had prostate irradiation and more patients with T3-T4 disease that had pelvic irradiation

    Results

  • Median hemoglobin values decreased in each group, though there was a broad range
  • Prostate XRT alone had a mean decrease of 0.29 g/dl
  • Whole pelvis XRT alone had a mean decrease of 0.78 g/dl
  • Prostate XRT + hormones and a mean decrease of 0.90 g/dl
  • Whole pelvis XRT + hormones had a mean decrease of 1.43 g/dl
  • Severe hemoglobin drops (>2g/dl) occurred in 2% of the prostate XRT alone group, but in 13-23% of the other groups. The most severe was the whole pelvis + hormone population

    Author's Conclusions

  • Minor changes in hemoglobin often occur
  • Significance decrease in hemoglobin occurs in a minority of patients, up to 23% of patients in the whole pelvis + hormone group
  • Radiation and hormones both supress hemoglobin levels, though the effect seems to be additive
  • It remains unclear whether this translates into a clinically significant detrimental effect on treatment

    Clinical/Scientific Implications
    Both radiation and hormonal ablation seem to decrease hemoglobin levels. However, except in the whole pelvis + hormone group, this drop is somewhat minor. The drop in this group is likely due to a combination of radiation and hormones, though comparing this population to the prostate radiation + hormones group, it appears this difference is due mainly to the pelvic radiation. As stated, it is unclear whether this translated into a clinically significant effect. Prospective studies looking at hemoglobin's effect on local control and the use of hematopoietic growth factors in combatting anemia should be done.

    Oncolink's ASTRO Coverage made possible by an unrestricted Educational Grant from Bristol-Myers Squibb Oncology and Pharmacia Oncology.


    News
    Also, hormone therapy plus radiation improves survival in intermediate-risk early-stage disease

    Mar 5, 2010 - While the investigational drug cabazitaxel prolongs survival in men with metastatic prostate cancer progressing after treatment with a docetaxel-containing regimen, hormone therapy plus radiation improves survival and reduces recurrence in men with intermediate-risk early-stage prostate cancer, according to two studies presented at the 2010 Genitourinary Cancers Symposium, held from March 5 to 7 in San Francisco.


    Frequently Asked Questions

    National Cancer Institute

    Conferences

  • I Wish You Knew

    How cancer patients have changed my life

    View More



    Blogs and Web Chats

    OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




    OncoLink OncoPilot

    Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

    Más información